Abstract. In the present study, we sought to elucidate the effect of miR-145 on glioma cell progression and its mechanisms of action. We examined the effects of miR-145 on proliferation and invasion of U87 glioma cells and on capillary tube formation. Our data show that restoration of miR-145 in U87 glioma cells significantly reduced their *in vitro* proliferation, invasion and angiogenesis. However, decreased miR-145 expression promoted U87 glioma cell proliferation, invasion and angiogenesis, and reduced-expression of miR-145 increased ADAM17 and EGFR expression in U87 cells. Overexpression of miR-145 reduced ADAM17 and EGFR expression. VEGF secretion and VEGF expression were decreased by increased miR-145 expression in U87 cells and were reversed by miR-145 down-regulation in *vitro*. Nude mice with intracerebral implantation of U87 overexpressing miR-145 cells exhibited significantly reduced tumor growth and promoted survival compared with control groups. Taken together, these results suggest a role for miR-145 as a tumor suppressor which inhibits glioma cell proliferation, invasion and angiogenesis *in vitro* and reduces glioma growth *in vivo*.

Introduction

High-grade gliomas are malignant as they are highly vascularized and invasive, and characterized by high incidence of recurrence and poor prognosis (1,2). The prognosis for patients with malignant gliomas has not significantly changed in recent years (3). Glioma cells infiltrate into the normal brain adjacent to the tumor causing treatment failure from conventional therapy, including surgery, radiotherapy and chemotherapy (4). Thus, median survival time has changed little and is ~15 months (1). Brain tumors constitute the second most frequent cause of cancer deaths in patients <15 years of age, the third cause for adult men, and the fourth cause in women aged 15-34 years (5). Malignant gliomas are highly fatal and often strike patients in their most productive years.

MiRNAs, a class of small, non-encoding RNAs that transcriptionally or post-transcriptionally modulate the expression of their target genes, and have been implicated as regulatory molecules in various cancers from lung, breast, colon, prostate, head and neck, including melanoma and glioma (6,7). MiRNAs may alter the functions of oncogenes and/or tumor suppressor genes, and therefore, impact the biological behavior of these cancers. miR-145 is a tumor-suppressive miRNA that has been recently implicated in the regulation of cell growth in tumor cells through targeting c-myc, EGFR, OCT4, and MUC1 (8-11). However, little has been reported on whether miR-145 is associated with glioma progression.

ADAM17 (a.k.a. TACE), is involved in the ectodomain shedding of multiple membrane-bound ligands and cytokines, it has been implicated in diverse biological processes, including growth and inflammation (12). Currently, ADAM17 is best known as the primary secretase responsible for releasing the soluble form of tumor necrosis factor-α (TNF-α) from the plasma membrane. Of particular interest, ADAM17 has recently been identified as the primary sheddase for multiple epidermal growth factor receptor (EGFR) pro-ligands (13). EGFR ligand-binding results in receptor self-dimerization, auto-phosphorylation and subsequent activation of downstream PI3K/AKT and Ras/MAPK/ERK signaling pathways (14-16). EGFR is the prototype of a family of receptors with tyrosine kinases that participate in the control of differentiation, proliferation, and cell survival, as well as in the development of tumors of epidermal origin (16-19). The expression of EGFR is frequently upregulated in human glioma, and its overexpression correlates with poor prognosis (19).

Recently, we have demonstrated that expression of miR-145 is significantly downregulated in glioma cells as compared with normal brain tissue (20). miR-145 directly targets ADAM17 and binds to 3' UTR of ADAM17 mRNA, decreasing...
ADAM17 protein expression. Our present study demonstrates that overexpression of miR-145 inhibits glioma cell proliferation, invasion, angiogenesis in vitro, and decreases glioma cell growth in an animal model, possibly through the mechanism of miR-145-related decrease of ADAM17 and EGFR protein expressions via the Erk/p-Erk pathway in U87 cells.

Materials and methods

Cell line and cell culture. Human glioblastoma U87, and mouse brain endothelial cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 50 mg/ml streptomycin. The U87 cells were maintained in a humidified 37°C incubator with 5% CO₂, fed every 3 days with complete medium, and subcultured when confluence was reached.

Transfection of U87 cells with miR-145 and MiRzip-145. The cDNAs encoding miR-145 and cel-67 were purchased from Genscript (Piscataway, NJ, USA). MiRzip-145 was purchased from System Biosciences (Mountain View, CA, USA). Transfections were done with the use of Lipofectamine 2000 (Invitrogen) and transfection efficiency was measured with CellTracker™ Green (Molecular Probes, Eugene, OR, USA) in PBS-T (0.3% Tween-20) at room temperature for 1 h, followed by incubation with primary antibodies against ADAM17 (Abcam, Cambridge, MA, USA), EGFR (Cell Signaling, Danvers, MA, USA), Erk, p-Erk and actin (Santa

Modified cell lines. Modified cell lines used in this study were stable transfection U87 cells with miR-145 cDNA plasmid stable transfection (U87-miR-145), U87 glioma cells with negative control cel-67 plasmid (U87-cel-67), and U87 glioma cells with MiRzip-145 (targeting miR-145) plasmid stable transfection (U87-zip-145). The stable transfection was performed according to the manufacturer's instructions. Briefly, 1.5x10⁵ U87 glioma cells were seeded onto a 6-well plate and incubated with 4 µg cDNA as suggested by the manufacturer. After 48 h, cells were selected using Puromycin (Sigma-Aldrich, St. Louis, MO, USA).

Growth curve. U87 cells (1x10⁴) were plated into each well of 24-well plates containing DMEM with FBS at a concentration of 10%. Every 24 h medium was removed, adherent cells were trypsinized, and the total cell number of each well was quantified with the use of a hemocytometer. Cell number was expressed as an average of counts from three wells per time point per group.

Bromodeoxyuridine incorporation assay. Cell proliferation was measured using BrdU incorporation assay. Forty thousand cells in 1,000 µl complete medium per well were plated into 24-well plates. After 48-h incubation, the culture medium was removed and cells were rinsed with PBS followed by incubation with BrdU (25 µg/ml) for 2 h and fixed in 4% paraformaldehyde for 30 min at room temperature. Following fixation, cells were incubated with 50% formaldehyde in 2X SSC at 65°C for 30 min and with 2N HCl at 37°C for 10 min. After incubation with 0.1 M boric acid at room temperature for 30 min, cells were rinsed with PBS and blocked with 1% bovine serum albumin at room temperature for 1 h, followed by incubation with an anti-BrdU antibody overnight at 4°C. Cells were then incubated with a FITC-conjugated secondary antibody to visualize BrdU positive labeled cells. Before mounting with coverslips, cells were incubated with 10 µg/ml of DAPI (4′,6-diamidino-2-phenylindole, Invitrogen) for 10 min. Four fields of cells were counted randomly in each well under a fluorescent microscope at x10 magnification. The proliferation rate was expressed as the percentage of BrdU positive labeled cells divided by DAPI labeled cells.

In vitro invasion assay. Matrigel chambers (BD Biosciences) were used to determine the effect of stable expression of miR-145 on invasiveness, according to the manufacturer’s protocol. Cells (1x10⁵) with stable transfection of miR-145, or zip-145 were plated into 6-well plates and incubated for 48 h. Then, glioma cells were re-suspended in 500 µl of serum-free medium and added to the upper chamber, while the lower chamber was filled with 0.5 ml of complete medium that served as a chemo-attractant. Cells were then incubated for 24 h at 37°C. After removal of cells from the upper surface of the membrane, cells on the lower surface of the membrane were stained with CellTracker™ Green (Molecular Probes, Eugene, OR, USA) for 30 min and fixed in 4% formaldehyde. Nine fields of cells were counted randomly in each well under a fluorescent microscope at x100 magnification. All the experiments were done in duplicate and results were expressed as mean ± SEM of three independent experiments.

Capillary-like tube formation assay. Briefly, 0.1 ml growth factor reduced Matrigel (Becton-Dickinson) was added per well, and mouse brain endothelial cells (MBECs, 2x10⁴ cells) were added and incubated in: i) regular cell culture medium (DMEM) for control; ii) cell culture medium from U87 only cell culture; iii) cell culture medium from U87 miR-145 cell culture; iv) cell culture medium from U87 zip-145 for ≤3 h. All assays were performed in triplicates. For quantitative measurements of capillary tube formation, Matrigel wells were digitized under a 4x objective (Olympus) for measurement of total tube length of capillary tube formation using the MCID image analysis system (Imaging Research, St. Catharines, Canada) at 3 h. Tracks of endothelial cells organized into networks of cellular cords (tubes) were counted and averaged in randomly selected three microscopic fields. The total tube length was calculated by MCID software in each field. The tube formation index was expressed as tube length (mm) per field.

Western blot analysis. Cultures were rinsed with PBS and proteins were extracted in 500 ml RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 0.1% SDS and 0.01% sodium azide, pH 7.4). Equal amounts of proteins, as determined by the BCA protocol (Pierce, Rockford, IL, USA), run on 10% Tris-glycine gels (Invitrogen) and then transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). The membranes were blocked with 0.1% I-Block (Applied Biosystems, Foster City, CA, USA) in PBS-T (0.3% Tween-20) at room temperature for 1 h, followed by incubation with primary antibodies against ADAM17 (Abcam, Cambridge, MA, USA), EGFR (Cell Signaling, Danvers, MA, USA), Erk, p-Erk and actin (Santa
Human glioma cell implantation in nude mice. Nude mice (Nu/Nu Athymic, Charles River Breeding, MA, USA) with body weight of 15-25 g were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) administered intraperitoneally (i.p.). After fixing the mouse in a stereotaxic device, the scalp was retracted to expose the cranium, and a 3-4-mm incision was made directly down the midline. With the use of a drill, a 2-mm craniotomy was made on the right hemisphere anterior to the coronal suture. A 10-ml Hamilton syringe was used to measure and confirm miR-145, zip-145 versus control U87 cells. As shown in Fig. 1, miR-145 expression level was significantly elevated (53.8-fold) in U87-145 cells compared with levels in control U87 cells. As for miR-145 overexpression in U87-zip-145 glioma cells, Fig. 1 shows that miR-145 expression level was significantly decreased to 0.4% compared to control U87 cells. The data suggested that stable transfection of miR-145 and zip-145 was established in the U87 cell lines.
decreased cell invasion by 63.6% in U87 (Fig. 3). However, the invasiveness of miRzip-145 transfected glioma cells was significantly increased by 1.53-fold compared to control cells. The *in vitro* invasion assay data indicated that the invasiveness of U87 glioma cells is related to miR-145 expression levels, and increase of miR-145 decreases the invasiveness in U87 cells.

Overexpression of miR‑145 inhibits tube formation in cultured mouse brain endothelial cells. To test the effect of miR-145 expression upon glioma-induced angiogenesis, we performed a tube-formation assay of mouse brain endothelial cells (MBECs) *in vitro*. As shown in Fig. 4, culture medium from U87 glioma overexpressing miR-145 significantly reduced capillary tube formation of mouse brain endothelial cells by 34.55% when compared to control U87 media. While down-regulation of miR-145 medium showed a significant 1.28-fold increase in MBECs capillary tube formation compared to control medium. These results suggest that miR-145 in glioma cells promotes angiogenesis.

Overexpression of miR-145 decreases VEGF in mRNA and soluble protein release levels. Real-time PCR was employed to measure VEGF mRNA expression level in U87 miR-145, U87 zip-145, and control U87 glioma cells (Fig. 4). VEGF expression level was significantly increased (3.16-fold) in U87 zip-145 cells, and was significantly decreased by 95.13% in U87 miR-145 cells compared to control cells. These results indicate that miR-145 regulates VEGF mRNA expression.

VEGF soluble protein release showed the same profile as mRNA levels in all experimental groups. miR-145, zip-145, control U87 cells were cultured under 37°C for 24 h to attached to the bottom of the 6-well plate, respectively. Following complete removal of medium 24 h later, glioma cells were rinsed by PBS and serum-free medium was added.
for another 24 h. Culture medium was then collected for analysis of soluble VEGF release from glioma cells (Fig. 4). High miR-145 expression decreased to 62.4% the VEGF release to supernatant by U87 miR-145, and low expression of miR-145 increased VEGF release to 2.4-fold by U87 zip-145.

**Figure 3.** Effect of miR-145 expression on glioma cell invasiveness in vitro. The 24-h in vitro Matrigel invasion assay revealed that miR-145 overexpression decreased glioma cell invasiveness by 63.6% compared to control cells, and the miR-145 downregulation significantly increased invasiveness by 1.53-fold compared to control cells. In vitro invasion assay indicated that the invasiveness of U87 glioma cells is correlated to miR-145 levels. *P<0.05 versus control.

**Figure 4.** miR-145 overexpression in glioma cells inhibits tube formation in MBECs. Culture medium from U87 miR-145 cells decreased MBECs capillary tube formation by 34.55% compared to control medium. Medium from U87 zip-145 cells promoted capillary tube formation by 1.28-fold compared to control. As compared with medium only, U87 conditioned medium increased the tube formation in MBECs. Overexpression of miR-145 significantly decreased VEGF expression in U87 miR-145 cells and soluble VEGF release after 24 h. While zip-145 significantly promoted VEGF expression in U87 zip-145 cells and soluble VEGF release. *P<0.05 versus control; **P<0.05 versus control.

**Figure 5.** Effect of miR-145 overexpression or downregulation on ADAM17/EGFR/ERK activation in U87 cells. miR-145 was reported to directly target ADAM17 and EGFR. ADAM17 and EGFR expression showed a significant decrease in U87 miR-145 cells and a significant increase in U87 zip-145 cells. Expression of p-Erk showed the same trend as ADAM17/EGFR, but expression of Erk was not significantly affected by miR-145 expression levels.
lower expression of ADAM17 and EGFR, respectively, in total protein levels, and lower phosphorylation state of Erk as compared with control groups. Furthermore, low expression of miR-145 in glioma cells was correlated to increased ADAM17 and EGFR expression. These data suggest that miR-145 significantly contribute to the pathways known to promote glioma cell malignancy.

miR-145 inhibits U87 glioma growth in nude mice. MiR145-overexpressing U87 glioma cells were transfected with negative plasmid cel-67, and: i) control; ii) cel-67; iii) miR-145; and iv) zip-145 U87 glioma cells were injected stereotactically (5x10⁵ cells/mouse) at a depth of 3.5 mm, 1.5 mm to the right of midline, and 1.0 mm anterior to the bregma. Animals were sacrificed at 30 days after tumor implantation. Tumor-bearing brain was processed, placed in paraffin, and subsequently seven equally spaced, 6 µm sections, were obtained from each of the 1-mm blocks encompassing the tumor. The sections were stained with H&E for light microscopic examination and analysis. After 30 days, miR-145 transfected U87 cells showed a significant decrease in tumor volume (Fig. 6) in nude mice compared to control cells and parent glioma cells transfected with cel-67. As shown in Fig. 6, zip-145 transfected U87 cells grew to form a solid tumor and showed no significant increase in tumor volume in comparison with control. The nude mice with U87 zip-145 cell implantation died 14 days after implantation. These data indicate that miR-145 significantly contributes to glioma xenograph growth, and suggests overexpression of miR-145 may have therapeutic antitumor effects for glioma.

Discussion

Glioblastoma is the most common primary brain tumor in adults. Almost all high-grade gliomas will invariably recur due to their extensive invasion into the surrounding brain tissue supported by their high capacity of neovascularization (21). These features cause treatment failure and have a very high mortality rate by conventional therapies. ADAMs are an important family of proteins upregulated in many cancers including glioma (22,23). miR-145 has been reported to target and regulate ADAM17, an important ADAM family member (20,24). In addition, accumulated evidence showed that the non-coding miRNAs have multi-function on gene regulation during tumor progression (25).

In the present study, the U87 human glioblastoma cell line was employed to investigate to the effect of miR-145 on glioma cell proliferation, invasion, and angiogenesis in vitro. Overexpression and downregulation of miR-145 were established with transfection of miR-145 and zip-145 plasmids, respectively. Growth curve and BrdU incorporation assays were employed to examine the effect of miR-145 on U87 glioma cell proliferation. Our data demonstrate that miR-145 decreases U87 glioma cell proliferation. Decrease of miR-145 by zip-145 significantly increased tumor cell proliferation. These data suggest that miR-145 plays a key role in U87 cell malignancy. We used Matrigel invasion assays to assess the ability of glioma cells to penetrate the ECM. Our data showed that the invasion potential of U87 cells is decreased by miR-145 overexpression, and increased by miR-145 downregulation.

Neovascularization plays critical roles in the process of embryo development, tissue differentiation and repair, inflammatory diseases, and tumor growth and metastasis (26,27). During the angiogenic process, endothelial cells digest the basement membrane of the vessel, migrate through the membrane while they proliferate in number, form a new vessel lumen and then sprout into a new vessel branch (28). Proliferation and growth of tumor cells consume oxygen in solid tumors. The hypoxia and necrosis resulting from rapid growth triggers the angiogenic switch out of the vascular quiescent state, which subsequently supports tumor progression (29). The initiation of newly formed tumor vessels also known as neovascularization or angiogenesis requires proangiogenic growth factors including vascular endothelial growth factor (VEGF) and related molecules. VEGF can be triggered by extracellular signals such as transforming growth factor α (TGF-α) and hypoxia-inducible factor 1-α (HIF-α), and internal genetic change (29,30). ADAM17 and EGFR increase the expression of HIF-α, and HIF-α then activates...
VEGF and VEGFR to stimulate tumor angiogenesis (22,31). To address the function of miR-145 on glioma angiogenesis, we further tested VEGF expression in U87 cells and angiogenesis in vitro with mouse brain endothelial cells cultured in supernatant from U87 cells. Real-time PCR, soluble protein, and tube formation assays demonstrated that high expression of miR-145 leads to a decrease in gene, protein and functional levels of VEGF. VEGF plays an important role in glioma progression. An in vitro capillary tube formation assay was employed to determine the effect of miR-145 on angiogenesis. Our data suggest that miR-145 decreased capillary-like tube formation. However, downregulation of miR-145 reverses the capacity of tube formation that was associated with lowered VEGF expression. Therefore, our data suggest downregulation of VEGF expression may be one of mechanisms by which miR-145 inhibits angiogenesis. We found that miR-145 expression was inversely correlated with VEGF mRNA, in addition to VEGF protein. This suggests that the effect of miR-145 upon VEGF may be indirect, rather than via translational inhibition. It is also likely that other factors or pathways are involved in the regulation of neovascularization. Therefore, further investigation of other signaling factors or pathways is warranted.

In our in vivo study, the data indicate that miR-145 is a growth inhibitor in U87 human glioma progression. Stable transfection with a plasmid encoding miR-145 leads to inhibition of the malignant phenotype. miR-145 overexpression decreased the rate of tumor growth in U87-miR-145 glioma bearing nude mice as compared with those parent tumor control and negative tumor control. Downregulation of miR-145 promotes tumor invasion and tumor growth. These data confirmed our in vivo result that increased miR-145 expression decreases glioma proliferation.

ADAM17 is a primary sheddase for multiple EGFR pro-ligands, such as HB-EGF and TGF-α (13,32). EGFR can be activated by its ligands including EGF, TGF-α, amphiregulin, and betacellulin (14,33). It is the first identified receptor tyrosine kinase (34). EGFR is amplified and overexpressed in tumors of many tissues (35-37). EGFR and its downstream signaling pathway is a key regulator of cell proliferation and it is frequently deregulated in cancer (38,39). EGFR ligand-binding results in receptor self-dimerization, autophosphorylation, and subsequent activation of downstream PI3K/AKT and Ras/MAPK pathways, which are responsible for the malignant phenotype (14,15). Furthermore, we examined the mechanisms by which ADAM17/EGFR/MAPK/ ERK pathway contributed to miR-145-induced inhibition on glioma proliferation, invasion, and angiogenesis after transfection of miR-145. High expression of miR-145 resulted in a significant decrease in U87 cell proliferation, invasion and angiogenesis. Coincidentally, miR-145 overexpression deactivated ADAM17/EGFR/ERK in vitro, and downregulation of miR-145 increased ADAM17/EGFR/ERK activation. These data further indicate that miR-145 overexpression contributes to reduction of tumor progression through deactivation of the ADAM17/EGFR/ERK pathway.

Acknowledgements

This study was supported by the National Institutes of Health grant RO1 CA12944 (F.J.). We thank Cindi Roberts and Qinge Lu for technical assistance on histology. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health.

References

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
3. Beauchesne P: Fotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas. Cancers (Basel) 4: 77-87, 2012.
4. Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B and Cruceru ML: Anti-cancer therapies in high grade gliomas. Curr Proteomics 10: 246-260, 2013.
5. Wang F, Xia J, Wang N and Zong H: miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc. Oncology 36: 754-758, 2013.
6. Cho WC, Chow AS and Au JS: MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGF and NUDT1. RNA Biol 8: 125-131, 2011.
7. Nacheva M and Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70: 378-387, 2010.
8. Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30, 2003.
9. Lee DC, Sunnarborg SW, Hinkle CL, et al: TACE/ADAM17 processing of EGF ligands indicates a role as a physiological convertase. Ann NY Acad Sci 995: 22-38, 2003.
10. Wells A: EGF receptor. Int J Biochem Cell Biol 31: 637-643, 1999.
11. Lal A, Glazer CA, Martinson HM, et al: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62: 3335-3339, 2002.
12. Datta SR, Brunet A and Greenberg ME: Cellular survival: a play in three Acts. Genes Dev 13: 2905-2927, 1999.
13. Maher EA, Furnari FB, Bachoo RM, et al: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001.
14. Wechsler-Reya R and Scott MP: The developmental biology of brain tumors. Annu Rev Neurosci 24: 385-428, 2001.
15. Mineo JF, Quintin-Roue I, Lucas B, Buburusan V and Besson G: Glioblastomas: clinical study and search for prognostic factors. Neurochirurgie 48: 498-500, 2002 (In French).
16. Lu Y, Chopp M, Zheng X, Katakowski M, Buller B and Jiang F: MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncol Rep 29: 67-72, 2013.
17. Nieto-Sampedro M, Valle-Argos B, Gomez-Nicola D, Fernandez-Mayoralas A and Nieto-Diaz M: Inhibitors of glioma growth that reveal the tumour to the immune system. Clin Med Insights Oncol 5: 265-314, 2011.
18. Zheng X, Jiang F, Katakowski M, Lu Y and Chopp M: ADAM17 promotes glioma cell malignant phenotype. Mol Cancerog 51: 150-164, 2012.
19. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant phenotype through EGFR-P13K-AKT activation. Cancer Biol Ther 8: 1045-1054, 2009.
20. Doberstein K, Steinfleury N, Hartmetz AK, et al: MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 15: 218-230, 2013.
25. Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865, 2013.
26. Furuya M, Nishiyama M, Kasuya Y, Kimura S and Ishikura H: Pathophysiology of tumor neovascularization. Vasc Health Risk Manag 1: 277-290, 2005.
27. Folkman J: Angiogenesis. Annu Rev Med 57: 1-18, 2006.
28. Ausprunk DH and Folkman J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14: 53-65, 1977.
29. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
30. Perry BN and Arbiser JL: The duality of angiogenesis: implications for therapy of human disease. J Invest Dermatol 126: 2160-2166, 2006.
31. Goldman CK, Kim J, Wong WL, King V, Brock T and Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-133, 1993.
32. Ruhe JE, Streit S, Hart S and Ullrich A: EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. Cell Signal 18: 1515-1527, 2006.
33. Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565, 2000.
34. Ullrich A, Coussens L, Hayflick JS, et al: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984.
35. Chaffanet M, Chauvin C, Laine M, et al: EGF receptor amplification and expression in human brain tumours. Eur J Cancer 28: 11-17, 1992.
36. Horak E, Smith K, Bromley L, et al: Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6: 2277-2284, 1991.
37. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS and Stokoe D: Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 4: 1369-1372, 2005.
38. Kenny PA: Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem Soc Trans 35: 665-668, 2007.
39. Kenny PA: TACE: a new target in epidermal growth factor receptor dependent tumors. Differentiation 75: 800-808, 2007.